Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase

Virus Research

Volumn 134, Issue 1-2, 2008, Pages 157-170

  Ren, Jingshan ^a   Stammers, David K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Drug resistance; HIV; NNRTI; Non nucleoside inhibitor; Reverse transcriptase

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; CAPRAVIRINE; CP 94707; DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; ETRAVIRINE; GCA 186; GW 4511; MSK 076; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TNK 651; TYROSINE DERIVATIVE; UC 38;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVERSE TRANSCRIPTION; RING OPENING; STEREOCHEMISTRY; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 43049144549     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.12.018     Document Type: Article

References (65)

1. Auwerx J., Stevens M., Van Rompay A.R., Bird L.E., Ren J., De Clercq E., Oberg B., Stammers D.K., Karlsson A., and Balzarini J. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. J. Virol. 78 (2004) 7427-7437
2. Buckheit R.W., Kinjerski T.L., Fliakas-Boltz V., Russell J.D., Stup T.L., Pallansch L.A., Brouwer W.G., Dao D.C., Harrison W.A., Schultz R.J., Bader J.P., and Yang S.S. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39 (1995) 2718-2727
3. Chan J.H., Hong J.S., Hunter III R.N., Orr G.F., Cowan J.R., Sherman D.B., Sparks S.M., Reitter B.E., Andrews III C.W., Hazen R.J., St Clair M., Boone L.R., Ferris R.G., Creech K.L., Roberts G.B., Short S.A., Weaver K., Ott R.J., Ren J., Hopkins A., Stuart D.I., and Stammers D.K. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 44 (2001) 1866-1882
4. Chan J.H., Freeman G.A., Tidwell J.H., Romines K.R., Schaller L.T., Cowan J.R., Gonzales S.S., Lowell G.S., Andrews III C.W., Reynolds D.J., St Clair M., Hazen R.J., Ferris R.G., Creech K.L., Roberts G.B., Short S.A., Weaver K., Koszalka G.W., and Boone L.R. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 47 (2004) 1175-1182
5. Das K., Ding J., Hsiou Y., Clark A.D., Moereels H., Koymans L., Andries K., Pauwels R., Janssen P.A., Boyer P.L., Clark P., Smith R.H., Kroeger Smith M.B., Michejda C.J., Hughes S.H., and Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264 (1996) 1085-1100
6. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., De Bethune M.P., Boyer P.L., Clark P., Hughes S.H., Janssen P.A., and Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47 (2004) 2550-2560
7. Das K., Sarafianos S.G., Clark Jr. A.D., Boyer P.L., Hughes S.H., and Arnold E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 365 (2007) 77-89
8. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47 (1994) 155-169
9. De Clercq E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8 (2001) 1543-1572
10. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., and Arnold E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 2 (1995) 407-415
11. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S.Y., Stevenson M., and Tarpley W.G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4713-4717
12. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., and Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2 (1995) 303-308
13. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., and Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this non-nucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3984-3989
14. Esnouf R.M., Ren J., Garman E.F., Somers D.O.N., Ross C.K., Jones E.Y., Stammers D.K., and Stuart D.I. Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. Acta Crystallogr. D 54 (1998) 938-954
15. Freeman G.A., Andrews III C.W., Hopkins A.L., Lowell G.S., Schaller L.T., Cowan J.R., Gonzales S.S., Koszalka G.W., Hazen R.J., Boone L.R., Ferris R.G., Creech K.L., Roberts G.B., Short S.A., Weaver K., Reynolds D.J., Milton J., Ren J., Stuart D.I., Stammers D.K., and Chan J.H. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. J. Med. Chem. 47 (2004) 5923-5936
16. Fujiwara T., Sato A., el-Farrash M., Miki S., Abe K., Isaka Y., Kodama M., Wu Y., Chen L.B., Harada H., Sugimoto H., Hatanaka M., and Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42 (1998) 1340-1345
17. Goody R.S., Muller B., and Restle T. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminiating nucleotides in vivo. FEBS Lett. 291 (1991) 1-5
18. Hanna G.J., Johnson V.A., Kuritzkes D.R., Richman D.D., Brown A.J., Savara A.V., Hazelwood J.D., and D'Aquila R.T. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181 (2000) 904-911
19. Harrigan P.R., Salim M., Stammers D.K., Wynhoven B., Brumme Z.L., McKenna P., Larder B., and Kemp S.D. A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J. Virol. 76 (2002) 6836-6840
20. Himmel D.M., Das K., Clark Jr. A.D., Hughes S.H., Benjahad A., Oumouch S., Guillemont J., Coupa S., Poncelet A., Csoka I., Meyer C., Andries K., Nguyen C.H., Grierson D.S., and Arnold E. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J. Med. Chem. 48 (2005) 7582-7591
21. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., Miyasaka T., Walker R.T., Tanaka H., Stammers D.K., and Stuart D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39 (1996) 1589-1600
22. Hopkins A.L., Ren J., Tanaka H., Baba M., Okamato M., Stuart D.I., and Stammers D.K. Design of MKC-442 (Emivirine) analogues with improved activity against drug resistant HIV mutants. J. Med. Chem. 42 (1999) 4500-4505
23. Hopkins A.L., Ren J., Milton J., Hazen R.J., Chan J.H., Stuart D.I., and Stammers D.K. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J. Med. Chem. 47 (2004) 5912-5922
24. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Hughes S.H., and Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4 (1996) 853-860
25. Hsiou Y., Das K., Ding J., Clark A.D., Kleim J.-P., Rosner M., Winkler I., Riess G., Hughes S.H., and Arnold E. HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 284 (1998) 313-323
26. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Boyer P.L., Lewi P., Janssen P.A., Kleim J.P., Rosner M., Hughes S.H., and Arnold E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309 (2001) 437-445
27. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
28. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15 (2007) 119-125
29. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
30. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36 (1992) 2664-2669
31. Lindberg J., Sigurosson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., Fridborg K., Zhang H., and Unge T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 269 (2002) 1670-1677
32. Maga G., Amacker M., Ruel N., Hubscher U., and Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274 (1997) 738-747
33. Menéndez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134 (2008) 124-146
34. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.-K., Eckner K., Hattox S., Adams J., Rosenthal A.S., Faanes R., Eckner R.J., Koup R.A., and Sullivan J.L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250 (1990) 1411-1413
35. Mitsuya H., Yarchoan R., and Broder S. Molecular targets for AIDS therapy. Science 249 (1990) 1533-1544
36. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., and De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32 (1989) 2507-2509
37. Pata J.D., Stirtan W.G., Goldstein S.W., and Steitz T.A. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10548-10553
38. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Gelder J.V., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 (1990) 470-474
39. Pelemans H., Esnouf R.M., Jonckheere H., De Clercq E., and Balzarini J. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. J. Biol. Chem. 273 (1998) 34234-34239
40. Reed C., and Daar E.S. Novel antiretroviral agents in HIV therapy. Curr. Infect. Dis. Rep. 8 (2006) 489-496
41. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., and Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2 (1995) 293-302
42. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., and Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3 (1995) 915-926
43. Ren J., Esnouf R.M., Hopkins A.L., Warren J., Balzarini J., Stuart D.I., and Stammers D.K. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 37 (1998) 14394-14403
44. Ren J., Diprose J., Warren J., Esnouf R.M., Bird L.E., Ikemizu S., Slater M., Milton J., Balzarini J., Stuart D.I., and Stammers D.K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases: structural and biochemical analyses. J. Biol. Chem. 275 (2000) 5633-5639
45. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., and Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold. Des. 8 (2000) 1089-1094
46. Ren J., Nichols C.E., Bird L.E., Fujiwara T., Sugimoto H., Stuart D.I., and Stammers D.K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 RT involves extensive main chain hydrogen bonding. J. Biol. Chem. 275 (2000) 14316-14320
47. Ren J., Nichols C., Bird L., Chamberlain P., Weaver K., Short S., Stuart D.I., and Stammers D.K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 312 (2001) 795-805
48. Ren J., Bird L.E., Chamberlain P.P., Stewart-Jones G.B., Stuart D.I., and Stammers D.K. Structure of HIV-2 reverse transcriptase at 2.35 Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14410-14415
49. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., and Stammers D.K. Crystal structures of HIV-1 reverse transcriptase mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 336 (2004) 569-578
50. Ren J., Nichols C.E., Stamp A., Chamberlain P.P., Ferris R., Weaver K.L., Short S.A., and Stammers D.K. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. 273 (2006) 3850-3860
51. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., Chan J.H., Kleim J.P., and Stammers D.K. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. 50 (2007) 2301-2309
52. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., and Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68 (1994) 1660-1666
53. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., Woolf D.J., Debouck C., and Harrison S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1222-1226
54. Rodriguez-Barrios F., and Gago F. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. J. Am. Chem. Soc. 126 (2004) 15386-15387
55. Rodriguez-Barrios F., Perez C., Lobaton E., Velazquez S., Chamorro C., San-Felix A., Perez-Perez M.J., Camarasa M.J., Pelemans H., Balzarini J., and Gago F. Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p55 interface of HIV-1 reverse transcriptase. J. Med. Chem. 44 (2001) 1853-1865
56. Rodriguez-Barrios F., Balzarini J., and Gago F. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J. Am. Chem. Soc. 127 (2005) 7570-7578
57. Schweighardt B., Ortiz G.M., Grant R.M., Wellons M., Miralles G.D., Kostrikis L.G., Bartlett J.A., and Nixon D.F. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. Aids 16 (2002) 2342-2344
58. Sluis-Cremer N., and Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 134 (2008) 147-156
59. Sluis-Cremer N., Dmitrienko G.I., Balzarini J., Camarasa M.J., and Parniak M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]]]-3-ethylthy mine. Biochemistry 39 (2000) 1427-1433
60. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., and Steitz T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3911-3915
61. Spence R.A., Kati W.M., Anderson K.S., and Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 (1995) 988-993
62. Spence R.A., Anderson K.S., and Johnson K.A. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 35 (1996) 1054-1063
63. Stammers D.K., Stuart D.I., Ren J., Chamberlain P.P., Weaver K.L., Short S.A., Andrews C., Romines K., Boone L., Schaller L., Freeman A., and Chan J. Structural studies of benzophenone/HIV-1 RT complexes: insights into the potency of the next generation NNRTIs against WT and mutant HIV-1. Antivir. Ther. 9 (2004) S36
64. Xia Q., Radzio J., Anderson K.S., and Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 16 (2007) 1728-1737
65. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S., Pettibone D.J., O'Brien J.A., Ball R.G., Balani S.K., Lin J.H., Chen I.-W., Schleif W.A., Sardana V.V., Long W.J., Byrnes V.W., and Emini E.A. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39 (1995) 2602-2605